The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: A review

被引:42
作者
Grinblat, Beni [1 ]
Scheinberg, Morton [2 ]
机构
[1] Hosp Israelita Albert Einstein, Sao Paulo, Brazil
[2] Hosp Israelita Albert Einstein & Res Inst, Sao Paulo, Brazil
关键词
psoriasis; psoriatic arthritis; anti TNF agents;
D O I
10.1016/j.semarthrit.2007.05.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The paradoxical observation that antitumor necrosis factor (anti-TNF) agents are capable of inducing psoriasis and psoriasiform skin lesions while also being therapy for psoriasis gained substantial support following the description of this condition by several authors. Our aim was to review the literature of this subject. Methods: A retrospective review of the literature was performed using the Medline database between 2005 and February 2007. Results: Since the first publication by our group in April 2005 to the present, 50 cases of this type of dermatitis have been described. More than half of the cases were associated with the use of infliximab. Different presentations of psoriasis were reported, plaque form being the most prevalent. A number of clinical and immunological observations suggest a cytokine disequilibrium in patients receiving chronic anti-TNF therapy leading to this condition. Treatment for the skin disease includes changing the anti-TNF agent or discontinuing the medication. Conclusions: The appearance of psoriasis and psoriasiform lesions during chronic anti-TNF therapy is dependent on the presence of known and unknown interrelated factors. Enhanced clinician awareness of this drug complication and further investigation of its mechanisms are warranted. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:251 / 255
页数:5
相关论文
共 44 条
[1]   Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis [J].
Asumalahti, K ;
Ameen, M ;
Suomela, S ;
Hagforsen, E ;
Michaëlsson, G ;
Evans, J ;
Munro, M ;
Veal, C ;
Allen, M ;
Leman, J ;
Burden, AD ;
Kirby, B ;
Connolly, M ;
Griffiths, CEM ;
Trembath, RC ;
Kere, J ;
Saarialho-Kere, U ;
Barker, JNWN .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 120 (04) :627-632
[2]   Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? [J].
Baeten, D ;
Kruithof, E ;
Van den Bosch, F ;
Van den Bossche, N ;
Herssens, A ;
Mielants, H ;
De Keyser, F ;
Veys, EM .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (09) :829-834
[3]   Autoimmunity through cytokine-induced dendritic cell activation [J].
Banchereau, J ;
Pascual, V ;
Palucka, AK .
IMMUNITY, 2004, 20 (05) :539-550
[4]   Interferon and granulopoiesis signatures in systemic lupus erythematosus blood [J].
Bennett, L ;
Palucka, AK ;
Arce, E ;
Cantrell, V ;
Borvak, J ;
Banchereau, J ;
Pascual, V .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (06) :711-723
[5]   Skin reaction to adalimumab [J].
Beuthien, W ;
Mellinghoff, HU ;
von Kempis, J .
ARTHRITIS AND RHEUMATISM, 2004, 50 (05) :1690-1692
[6]  
BONGARTZ T, 2006, JAMA-J AM MED ASSOC, V17, P295
[7]   Tumour necrosis factor inhibition causing psoriasis? A more plausible explanation exists [J].
Carter, J. D. .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (12) :1680-1680
[8]  
Cohen JD, 2007, J RHEUMATOL, V34, P380
[9]   Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor α inhibitors [J].
Deng, A ;
Harvey, V ;
Sina, B ;
Strobel, D ;
Badros, A ;
Junkins-Hopkins, JM ;
Samuels, A ;
Oghilikhan, M ;
Gaspari, A .
ARCHIVES OF DERMATOLOGY, 2006, 142 (02) :198-202
[10]   Psoriatic lesions induced by antitumour necrosis factor-α treatment:: two cases [J].
Dereure, O ;
Guillot, B ;
Jorgensen, C ;
Cohen, JD ;
Combes, B ;
Guilhou, JJ .
BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 (02) :506-507